摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-bromo-7,8-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-9(6H)-one

中文名称
——
中文别名
——
英文名称
2-bromo-7,8-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-9(6H)-one
英文别名
2-bromo-7,8-dihydro-6H-pyrido[1,2-a]benzimidazol-9-one
2-bromo-7,8-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-9(6H)-one化学式
CAS
——
化学式
C11H9BrN2O
mdl
——
分子量
265.109
InChiKey
FCZUFPIBXODVCC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    34.4
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    2-bromo-7,8-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-9(6H)-one三乙基硅烷三氟化硼乙醚 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 2.5h, 生成 2-(2-bromo-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-9-yl)phenol
    参考文献:
    名称:
    [EN] TRICYCLIC MODULATORS OF TNF SIGNALING
    [FR] MODULATEURS TRICYCLIQUES DE LA SIGNALISATION DU TNF
    摘要:
    这项发明提供了三环杂环化合物,其药用盐、前药、生物活性代谢物、立体异构体和同分异构体,其中变量在此处定义。该发明的化合物可能对治疗免疫和肿瘤疾病有用。
    公开号:
    WO2016168641A1
  • 作为产物:
    参考文献:
    名称:
    [EN] TARGETED BIFUNCTIONAL DEGRADERS
    [FR] AGENTS DE DÉGRADATION BIFONCTIONNELS CIBLÉS
    摘要:
    本发明在一个方面提供了可以用来促进或增强降解某些循环蛋白的双功能化合物。在另一个方面,本发明提供了可以用来促进或增强降解某些自身抗体的双功能化合物。在某些实施方式中,治疗或管理疾病和/或疾病需要降解、去除或减少受试者体内循环蛋白或自身抗体的浓度。因此,在某些实施方式中,将本发明的化合物给予受试者可去除或减少循环蛋白或自身抗体的循环浓度,从而治疗、改善或预防疾病和/或疾病。在某些实施方式中,循环蛋白是TNF。
    公开号:
    WO2021072269A1
点击查看最新优质反应信息

文献信息

  • [EN] TRICYCLIC MODULATORS OF TNF SIGNALING<br/>[FR] MODULATEURS TRICYCLIQUES DE LA SIGNALISATION DU TNF
    申请人:ABBVIE INC
    公开号:WO2016168641A1
    公开(公告)日:2016-10-20
    The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    这项发明提供了三环杂环化合物,其药用盐、前药、生物活性代谢物、立体异构体和同分异构体,其中变量在此处定义。该发明的化合物可能对治疗免疫和肿瘤疾病有用。
  • Elements as Direct Feedstocks for Organic Synthesis: Fe/I<sub>2</sub>/O<sub>2</sub> for Diamination of 2-Cyclohexenones with 2-Aminopyrimidine and 2-Aminopyridines
    作者:Thanh Binh Nguyen、Mathilde Corbin、Pascal Retailleau、Ludmila Ermolenko、Ali Al-Mourabit
    DOI:10.1021/acs.orglett.5b02340
    日期:2015.10.16
    Elements as feedstocks for organic synthesis, the trio of metallic iron, molecular iodine, and dioxygen, were found to be an excellent tool for oxidative regioselective diamination of conjugated enones with 2-aminopyrimidine (a guanidine surrogate) and 2-aminopyridines leading to unaromatized coupled products in moderate to good yields.
    发现三价金属铁,分子碘和双氧作为有机合成的原料,是用2-氨基嘧啶(一种胍替代物)和2-氨基吡啶氧化共轭烯酮进行氧化区域选择性渗氨的极佳工具,可导致未芳构化偶联产品产量中等至良好。
  • Iodine/Copper Iodide-Mediated C–H Functionalization: Synthesis of Imidazo[1,2-<i>a</i>]pyridines and Indoles from <i>N</i>-Aryl Enamines
    作者:Jing Liu、Wei Wei、Ting Zhao、Xuanyu Liu、Jie Wu、Wenquan Yu、Junbiao Chang
    DOI:10.1021/acs.joc.6b01960
    日期:2016.10.7
    A practical intramolecular C–H functionalization reaction of N-aryl enamines has been carried out with molecular iodine (I2) as the sole oxidant in the presence of copper iodide (CuI). The efficient and versatile synthetic method described here is compatible with both N-heteroaryl and N-aryl substituted enamines and produces diverse imidazo[1,2-a]pyridine and indole derivatives via I2-mediated oxidative
    在碘化铜(CuI)存在下,以分子碘(I 2)为唯一氧化剂,进行了N-芳基烯胺的分子内C–H官能化反应。本文所述的高效且通用的合成方法与N-杂芳基和N-芳基取代的烯胺兼容,并通过I 2生成各种咪唑并[1,2- a ]吡啶和吲哚衍生物介导的氧化性C–N和C–C键的形成。这种无配体的C–H官能化方法也可以与粗制烯胺一起使用,这可以直接从芳胺和酮(或炔烃)直接合成产物,而无需纯化烯胺中间体。
  • Hypervalent Iodine(III)‐Mediated Counteranion Controlled Intramolecular Annulation of Exocyclic β‐Enaminone to Carbazolone and Imidazo[1,2‐<i>a</i>]pyridine Synthesis
    作者:Dhananjay Bhattacherjee、Shankar Ram、Arvind Singh Chauhan、Yamini、Sheetal、Pralay Das
    DOI:10.1002/chem.201806299
    日期:2019.4.23
    A highly efficient and flexible protocol for intramolecular annulation of exocyclic β‐enaminones has been disclosed for the synthesis of carbazolones and imidazo[1,2‐a]pyridines through a counter‐anion‐controlled free‐radical mechanism promoted by hypervalent iodine(III). The cooperative behavior of HTIB and AgSbF6 plays a crucial role in the intramolecular annulation process through C−C and C−N bond
    为环外β-烯胺酮的分子内环化一个高效和灵活的协议已经公开了carbazolones和咪唑并[1,2的合成一个]吡啶通过高价碘促进的抗衡阴离子控制自由基机理(III) 。HTIB和AgSbF 6的协同行为在通过CC和CN键形成所需的分子内环化过程中起着至关重要的作用。机械学的见解表明,系统中涉及的两个竞争性反应是由抗衡阴离子的性质决定的,抗衡阴离子的性质决定了最终产物的形成。制备并分离了各种咔唑酮和咪唑并[1,2- a ]吡啶分子,收率良好至极佳。
  • Tricyclic modulators of TNF signaling
    申请人:AbbVie Inc.
    公开号:US10266532B2
    公开(公告)日:2019-04-23
    The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    本发明提供了三环杂环化合物、药学上可接受的盐、原药、生物活性代谢物、立体异构体和异构体,其中的变量在本文中定义。本发明的化合物可用于治疗免疫学和肿瘤学疾病。
查看更多

同类化合物

3H-1,4,8B-三氮杂苊烯e-3,5(4H)-二酮 3,4-bis(hydroxymethyl)dipyrido[1,2-a;3',4'-d]imidazole 3-methyldipyrido[1,2-a;3',4'-d]imidazole 2-methyl-6,7,8,9-tetrahydropyrido<1,2-a>benzimidazole 6,7,8,9-tetrahydrobenzo[4,5] imidazo[1,2-a]pyridin-3-amine 3-bromo-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine N-[1-[3-(3-cyanophenyloxy)propan-1-yl]piperidin-4-yl]-5-thia-1,8b-diazaacenaphthylene-4-carboxamide N-[1-[3-(2-cyanophenyloxy)propan-1-yl]piperidin-4-yl]-5-thia-1,8b-diazaacenaphthylene-4-carboxamide 4,5-dihydro-4-[4-(tert-butoxycarbonylamino)butan-1-yl]-3H-1,4,8b-triazaacenaphthylene-3,5-dione diethyl 5-hydroxy-3-thia-1,8b-diazaacenaphthylene-2,4-dicarboxylate 5-thia-1,8b-diazaacenaphthylene-4-carbaldehyde 2-bromo-7,8-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-9(6H)-one 2-(2-morpholinopyrimidin-5-yl)-7,8-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-9(6H)-one 9H-imidazo[1,2-a]pyrrolo[2,3-c]pyridine 8-chloro-1-[2-(difluoromethoxy)phenyl]-3,4-dihydro-1H-pyrano[4',3':4,5]imidazo[1,2-a]pyridine 6-methoxymethyl-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydro-imidazo[2,1-a]isoquinoline 4,5-dihydro-4-(tert-butoxycarbonyl)-3H-1,4,8b-triazaacenaphthylen-3-one imidazo<4',5':4,5>imidazo<1,2-a>pyridine">1,10-diethylpyrido<1",2":1',2'>imidazo<4',5':4,5>imidazo<1,2-a>pyridine imidazo<4',5':4,5>imidazo<1,2-a>pyridine">1,10-dimethylpyrido<1",2":1',2'>imidazo<4',5':4,5>imidazo<1,2-a>pyridine 1,3,4-trifluoro-dipyrido[1,2-a;3',4'-d]imidazole 3-(cyclopropyl)pyrano[3',4':4,5]imidazo[1,2-a]pyridinone 3-[(N-benzyl-N-methylamino)methyl]pyrano-[3',4':4,5]imidazo[1,2-a]pyridin-1-one 2-chloro-8-hydroxymethylene-6,7,8,9-tetrahydropyrido[1,2-a]benzimidazol-9-one ethyl 7-nitro-1H-imidazo<1,2-a>pyrazolo<3,4-c>pyridine-8-carboxylate 1-oxopyrido(1',2':1,2)imidazo[5,4-d]-1,2,3-triazine 3-methyl-2-[5-(amino)pentan-1-ylthio]-1,4,7b-triazacyclopent[cd]indene 1-methyl-3-pentyldipyrido[1,2-a:3',4'-d]imidazole 3-cyclopropyl-1-methyldipyrido[1,2-a:3',4'-d]imidazole 8-oxo-2,7,9-trimethylimidazo<4.5-c>imidazo<1.2-a>pyridine 1,3,7b-triazacyclopentinden-4(3H)-one 2-(2'-adamantyl)-8-oxo-7,9-dimethylimidazo<4.5-c>imidazo<1.2-a>pyridine ((7R,8S)-3-(1,3,4-oxadiazol-2-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate (7R,8S)-3-(1,2,4-oxadiazol-5-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-amine tert-butyl ((7R,8S)-3-(1H-tetrazol-5-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate tert-butyl ((7R,8S)-3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate tert-butyl ((7R,8S)-3-(2-methyl-2H-tetrazol-5-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate (7R,8S)-3-(2-methyl-2H-tetrazol-5-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-amine 5-((7R,8S)-8-amino-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one tert-butyl ((7R,8S)-3-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate tert-butyl ((7R,8S)-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate 5-((7R,8S)-8-amino-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-3-yl)-1,2,4-oxadiazol-5(4H)-one tert-butyl ((7R,8S)-3-((Z)-carbamohydrazonoyl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate (7R,8S)-8-amino-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (7R,8S)-3-(1,2,4-oxadiazol-3-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-amine 3-((7R,8S)-8-amino-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-3-yl)-4-methyl-1,2,4-oxadiazol-5(4H)-one ((7R,8S)-3-(1H-tetrazol-5-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate (7R,8S)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-amine tert-butyl ((7R,8S)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate tert-butyl ((7R,8S)-3-cyano-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate (7R,8S)-3-(1,3,4-oxadiazol-2-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-amine